Can a Complete Blood Count (CBC) be neutrophilic in patients with Rheumatoid Arthritis (RA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can CBC Show Neutrophilia in Rheumatoid Arthritis?

Yes, CBC can show neutrophilia in rheumatoid arthritis patients, as elevated neutrophil counts are a common finding that reflects active inflammation and disease activity. 1, 2

Neutrophilia as a Marker of RA Activity

  • Neutrophil counts are significantly elevated in RA patients compared to healthy controls, and this elevation correlates with disease activity measures. 2

  • The neutrophil-to-lymphocyte ratio (NLR) is elevated in RA patients (mean 2.53 ± 1.4 vs. 2.16 ± 1.0 in controls, P = 0.019) and increases progressively with worsening disease activity: 2.1 in remission, 2.5 in low-moderate activity, and 3.8 in high disease activity. 2

  • Neutrophils constitute over 90% of cells in rheumatoid synovial fluid, where they phagocytose immune complexes and release inflammatory mediators that perpetuate joint inflammation. 3

Clinical Utility of CBC in RA

  • CBC is recommended as part of the initial laboratory workup for polyarticular joint pain to exclude non-rheumatologic diseases and assess systemic involvement. 1

  • The neutrophil-to-monocyte ratio (NMR) has emerged as a superior inflammatory marker with an AUC of 0.861 (95% CI 0.769-0.948) at a cutoff of 4.7, demonstrating 87% sensitivity and 80% specificity for RA activity—performance equal to CRP and close to ESR. 4

  • CBC-derived inflammatory biomarkers (NLR, NMR) can assess disease activity and treatment response in RA, providing a readily available and inexpensive alternative to traditional markers. 5, 4

Monitoring Considerations

  • For patients on DMARDs (methotrexate, leflunomide, sulfasalazine), CBC monitoring is required every 2-4 weeks during the first 3 months, then every 8-12 weeks between 3-6 months, and every 12 weeks after 6 months of stable therapy. 6

  • For patients on tocilizumab, dose adjustments are recommended if neutropenia develops (500-1,000/mm³), as per package insert guidelines. 7

  • Persistent low neutrophil counts in stable disease may suggest underlying immunodeficiency rather than active RA, requiring further investigation. 7

Important Caveats

  • Neutrophilia reflects inflammation but is not specific to RA—other conditions including infections, malignancy, and inflammatory disorders can cause elevated neutrophil counts. 5

  • Thrombocytosis commonly accompanies neutrophilia in active RA, as platelet counts also correlate with inflammatory markers like CRP and IL-6. 8

  • The absolute neutrophil count (ANC) should be calculated from the differential, not just the percentage, for accurate assessment of neutrophilia. 7

References

Guideline

Initial Laboratory Workup for Polyarticular Joint Pain

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Laboratory Monitoring for Rheumatoid Arthritis Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Relationships between platelets and inflammatory markers in rheumatoid arthritis.

Clinica chimica acta; international journal of clinical chemistry, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.